Get notified of page updates

Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.

How to Use Our Search and Enroll Tool

Search Results: Treatment + Prostate Cancer (10 results)

Printer Friendly Page 1 through 10 of 10
Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor

Treatment
Treatment for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor

Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor

The study will test the safety and effectiveness of a new drug called TNG348 used alone or in combination with Olaparib (a PARP inhibitor.) The study is for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor.

Clinicaltrials.gov identifier: NCT06065059
More info
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.

Clinicaltrials.gov identifier: NCT05417594
More info
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Treatment
High-risk localized prostate cancer

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

This study will look at how well the PARP Inhibitor niraparib works, when given before a radical prostatectomy, for people with high-risk prostate cancer that has not spread to other parts of the body, and who have a tumor mutation in any of the following genes:BRCA1/2, ATM, CDK12, CHEK1/2 FANCA, FANCD2, FANCL, GEN1, NBN, PALB2, RAD51, RAD51c, and BRIP1.

.

Clinicaltrials.gov identifier: NCT04030559
More info
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

Treatment
Treatment study for people with advanced solid tumors

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.

Clinicaltrials.gov identifier: NCT04550494
More info
NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only. 

Clinicaltrials.gov identifier: NCT05252390
More info
Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

This study is comparing carboplatin chemotherapy to the drug, olaparib (a type of targeted therapy) as first-line treatment for metastatic castration-resistant prostate cancer in people with a BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L inherited mutation found through genetic testing, or tumor mutation found through biomarker testing.

Clinicaltrials.gov identifier: NCT04038502
More info
Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer (AVPC)

Treatment
Treatment in people with aggressive metastatic prostate cancer

Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer

This study will look at how well the combination of chemotherapy drugs (such as cabazitaxel and carboplatin), a PARP inhibitors (niraparib), and an immunotherapy agents (cetrelimab) works for treating people with a rare type of prostate cancer known as aggressive variant prostate cancer (AVPC). The research will compare the benefits of giving niraparib with or without cetrelimab, after treatment with chemotherapy.

Clinicaltrials.gov identifier: NCT04592237
More info
Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)

Treatment
Newly diagnosed prostate cancer grade group 3-5

Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)

This study will look at treating men with high risk prostate cancer using the PARP inhibitor, niraparib combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone. Phase 1 of this study will look at the best dose of niraparib for this treatment combination. The phase 2 portion of this study will look at the 3-year PSA recurrence free-survival rate of the patients who received this combined therapy.

Clinicaltrials.gov identifier: NCT04194554
More info
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.

Clinicaltrials.gov identifier: NCT04644068
More info
CYH33 in Combination With Olaparib in Patients With Advanced Solid Tumors and DNA Damage Repair Mutations

Treatment
Advanced solid tumors

Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations

This study will look at safety and effectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.

Clinicaltrials.gov identifier: NCT04586335
More info
Additional Results on Clinicaltrials.gov Treatment + Prostate Cancer + PARP
18 results
Clinical Trial Official Title
NCT05568550 Pembro With Radiation With or Without Olaparib
NCT04194554 A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
NCT04030559 Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
NCT04592237 Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
NCT04644068 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT05501548 Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
NCT04703920 Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT05498272 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations
NCT04550494 Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT04734730 Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT05700669 Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors
NCT05005728 XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02769962 Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
NCT06065059 Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
NCT05489211 Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT03682289 Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT05252390 NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT05417594 Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Research Search Tool Sponsored By: